Conference Coverage

AxSpA effects may be more severe for Black patients


 

AT SPARTAN 2023

Higher rates of nonradiographic axSpA among Black patients

The rate of nonradiographic axSpA among Black Americans was more than twice that of their White counterparts, which, Dr. Alexander noted, could make it more difficult to diagnose axSpA in that population.

The odds ratio for Black patients having nonradiographic axSpA, compared with Whites, was 2.265 (95% CI, 1.082-4.999; P = .035), after adjustment for age, sex, and HLA-B27 status.

Adult patients with axSpA were identified from rheumatology clinics at four major hospital systems and one private clinic in Shelby County, Tenn., between 2011 and 2021. Patients met modified New York (mNY) or Assessment of Spondyloarthritis International Society (ASAS) criteria as assessed by reviewers.

The authors and Dr. Alexander reported no relevant financial relationships.

Pages

Recommended Reading

Expert offers caveats to perioperative antirheumatic drug guideline
MDedge Rheumatology
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
MDedge Rheumatology
FDA approves new formulation of Hyrimoz adalimumab biosimilar
MDedge Rheumatology
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
MDedge Rheumatology
Meta-analysis examines cancer risk concern for JAK inhibitors
MDedge Rheumatology
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
MDedge Rheumatology
Axial spondyloarthritis versus axial psoriatic arthritis: Different entities?
MDedge Rheumatology
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
MDedge Rheumatology
Researchers make headway in understanding axSpA diagnostic delay
MDedge Rheumatology
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
MDedge Rheumatology